Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial.

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2018
This article has no abstract
Epistemonikos ID: fd4cc8f5c11d10ce392f9cf83683381aefc69fb5
First added on: Feb 10, 2025